Andrea F.
- Country
- Hungary
- Department
- VI. Pulmonológiai Osztály
Research Overview
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
- Evaluation of Adagrasib Dosing Regimens in Previously Treated KRAS G12C-Mutant Non-Small Cell Lung Cancer Patients
- Phase 2 Evaluation of AMG 193 Efficacy and Safety in MTAP-Deleted Advanced Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 59 of 281 partner sites.
Specializations
Non-Small Cell Lung Cancer
The clinical research activity centers on non-small cell lung cancer, including advanced, metastatic, locally advanced, and resectable disease. The portfolio includes studies in KRAS G12C-mutant, EGFR-altered, HER2-mutated, and PD-L1-selected populations, with strong interest in immunotherapy, targeted therapy, and perioperative treatment strategies.
- PD-1/PD-L1 and TIGIT-based immunotherapy
- KRAS G12C, EGFR, and HER2 targeted treatment
- Neoadjuvant, adjuvant, and first-line lung cancer care
- Metastatic and unresectable disease management
Research interest also extends to small cell lung cancer and biomarker-driven treatment selection across thoracic oncology.
Thoracic Immuno-Oncology
The investigator is involved in clinical studies of immune checkpoint inhibitors and combination regimens for lung malignancies, with emphasis on improving disease control in PD-L1-defined subgroups and treatment-refractory settings. This includes interest in antibody-based combinations and maintenance approaches for thoracic tumors.
- Immune checkpoint blockade
- Combination immunotherapy
- Biomarker-selected treatment strategies
- Post-chemoradiation and maintenance therapy
Key activity includes exploration of new immunotherapeutic approaches for advanced and unresectable thoracic cancers.
Small Cell Lung Cancer
Another major area of focus is small cell lung cancer, including extensive-stage and limited-stage disease. The research portfolio reflects interest in relapse prevention, survival outcomes, and treatment sequencing in aggressive lung cancer subtypes.
- Extensive-stage small cell lung cancer
- Limited-stage small cell lung cancer
- Second-line and later-line therapy
- Survival-focused treatment development
This work supports the evaluation of novel systemic options for patients with limited therapeutic alternatives.
Interstitial Lung Disease and Pulmonary Fibrosis
The investigator is active in studies of idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and progressive fibrosing interstitial lung diseases. Additional interest includes systemic sclerosis-associated interstitial lung disease, reflecting a broad commitment to fibrotic lung disorders and preservation of lung function.
- Idiopathic pulmonary fibrosis
- Progressive pulmonary fibrosis
- Progressive fibrosing interstitial lung disease
- Systemic sclerosis-associated interstitial lung disease
Clinical interest also includes therapies aimed at slowing functional decline in chronic fibrotic respiratory disease.
Chronic and Infectious Pulmonary Disease
The research profile also covers chronic obstructive pulmonary disease, asthma, bronchiectasis, cystic fibrosis, and pulmonary infections including nontuberculous mycobacterial lung infection and chronic pulmonary aspergillosis. Acute respiratory illness such as acute respiratory distress syndrome related to infection is also represented.
- Chronic obstructive pulmonary disease
- Asthma and bronchiectasis
- Cystic fibrosis
- Nontuberculous mycobacterial and fungal lung infection
These activities indicate involvement in both chronic airway disease and complex infectious pulmonary conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.